Jim Cramer recently discussed Moderna, Inc. (NASDAQ: MRNA), a struggling vaccine company post-COVID-19. The stock has dropped 42% year-to-date and 94% since its 2021 peak. Cramer questioned the firm’s value and suggested a price target of $18. He mentioned Moderna in light of recent vaccination requirement developments, stating concerns about politicization. While MRNA has investment potential, Cramer believes AI stocks offer better returns and lower risk. For those interested in cheap AI stocks, a report on a promising option is available. No specific recommendations were made in the article.

Read more at 1. Dow Jones Industrial Average closes at record high on strong earnings reports. – finance.yahoo.com

2. Amazon reports 43% increase in revenue, beating expectations. – finance.yahoo.com

3. Federal Reserve keeps interest rates unchanged, citing strong economic growth. – finance.yahoo.com

4. Tesla announces plans to build new factory in Texas, creating thousands of jobs. – finance.yahoo.com

5. Apple unveils new iPhone with improved camera and battery life. – finance.yahoo.com: I Thought Of Moderna, Inc. (MRNA) After Florida’s Vaccine Rules, Says Jim Cramer